Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

44 Press Releases
DateTitleCompany
25 Aug 15 CSL Behring Receives Marketing Authorization for Respreeza® in Europe CSL Behring,
Published by
Pharmiweb.com
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring,
Published by
Pharmiweb.com
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring,
Published by
PR Newswire
29 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring,
Published by
PharmiWeb.com
28 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
28 Jul 15 Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B CSL Behring,
Published by
PR Newswire
29 Jun 15 CSL Behring Receives Positive CHMP Opinion for Respreeza® (human alpha-1 proteinase inhibitor) as Maintenance Treatment for Patients with Severe Alpha-1 Antitrypsin Deficiency in Europe CSL Behring,
Published by
Business Wire
16 Jun 15 CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress CSL Behring,
Published by
PR Newswire
01 Jun 15 Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) CSL Behring,
Published by
PR Newswire
22 May 15 National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring,
Published by
PR Newswire
14 May 15 Science Information And Technology Driving Evolution Of Global Healthcare CSL Behring,
Published by
PR Newswire
30 Mar 15 European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients CSL BEHRING,
Published by
PR Newswire
27 Feb 15 CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia CSL BEHRING,
Published by
PR Newswire
04 Feb 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients CSL BEHRING,
Published by
PR Newswire
16 Dec 14 CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) for Hemophilia B Patients CSL BEHRING,
Published by
PR Newswire
04 Dec 14 CSL Issues "Our Corporate Responsibility 2014" Report CSL BEHRING,
Published by
PR Newswire
13 Oct 14 Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives CSL BEHRING,
Published by
PR Newswire
30 Sep 14 CSL Behring Expands Manufacturing Facility In Kankakee Illinois To Meet Patients' Growing Needs CSL BEHRING,
Published by
PR Newswire
16 Sep 14 CSL Behring Announces Last Patient Treated in Phase III Study of Fibrinogen Concentrate to Control Bleeding During Aortic Aneurysm Surgery CSL Behring,
Published by
Business Wire
05 Aug 14 bioCSL Inc. Launches AFLURIA® Shipping Campaign for 2014-2015 Seasonal Influenza bioCSL Inc.,
Published by
Business Wire
05 Dec 13 European Medicines Agency Approves Once Every Two Weeks Dosing Option For Hizentra®? (Human Normal Immunoglobulin, SCIg) CSL Behring UK Ltd,
Published by
Business Wire
03 Jul 12 CSL Behring launches new Hizentra®? Dosing Calculator App for Healthcare Professionals on the move CSL Behring UK,
Published by
CSL Behring UK Ltd
28 Jun 12 CSL Behring launches new Beriplex® P/N Dosing Calculator App for Healthcare Professionals on the move CSL Behring,
Published by
Munro & Forster
31 May 11 CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment CSL Behring,
Published by
PR Newswire
24 Feb 11 CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® to 30 Months CSL Behring,
Published by
Business Wire
18 Aug 10 CSL Behring Receives FDA Approval to Extend Shelf Life of Hizentra® from 18 Months to 24 Months CSL Behring,
Published by
Business Wire
09 Jun 10 Unique Hereditary Angioedema e-Learning Initiative Launched at 29th Congress of the European Academy of Allergy and Clinical Immunology CSL Behring,
Published by
PR Newswire
13 Apr 10 CSL Behring Seeking Proposals for LEAD Grants to Support Patient Advocacy Efforts CSL Behring,
Published by
Business Wire
05 Mar 10 CSL Behring Receives FDA Approval of HizentraTM, First 20 Percent Subcutaneous Immunoglobulin Therapy CSL Behring,
Published by
Business Wire
01 Mar 10 New Data Show IgPro20 Delivers Highest Available Subcutaneous Ig Concentration with Tolerability Comparable to Current Treatments CSL Behring,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.